Iterum Therapeutics (ITRM) has shared an update.
Iterum Therapeutics International Limited has contracted its outgoing Chief Medical Officer, Dr. Sailaja Puttagunta, as a consultant during the regulatory review of its new drug application for a urinary tract infection treatment. Dr. Puttagunta will be compensated at $400 per hour. Concurrently, the company is striving to regain compliance with Nasdaq Listing Rule 5550(b)(1) after being notified of a deficit in stockholders’ equity, with a deadline of September 30, 2024, to avoid delisting. Additionally, the FDA has acknowledged the resubmission of the company’s new drug application and set a review deadline for October 25, 2024.
For detailed information about ITRM stock, go to TipRanks’ Stock Analysis page.